SCHEMBL5375557

SCHEMBL5375557

COc1ccc2nc(N3CCN(CCCCC(N)C(=O)N4CCSC4)CC3)sc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
TP53 P04637 5/20 0.51
LMNA P02545 1/20 0.51
CYP2C9 P11712 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
DRD2 P14416 1/20 0.46
DRD3 P35462 1/20 0.46
HCRTR2 O43614 3/20 0.46
HCRTR1 O43613 2/20 0.46
ALDH1A1 P00352 3/20 0.45
GAA P10253 2/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
MITF O75030 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MAPK1 P28482 2/20 0.43
DPP7 Q9UHL4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5375546 1.00 MAPT (0.51) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2855166 0.94 MAPT (0.43) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2855160 0.94 MAPT (0.43) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2855953 0.88 NPC1 (0.53) MAPTSMN1; SMN2HCRTR2HCRTR1NPC1
SCHEMBL2855956 0.88 NPC1 (0.53) MAPTSMN1; SMN2HCRTR2HCRTR1NPC1
SCHEMBL2857447 0.86 DRD2 (0.44) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2857451 0.86 DRD2 (0.44) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2853973 0.86 DPP4 (0.49) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2853982 0.86 DPP4 (0.49) MAPTTP53LMNACYP2C9CYP1A2
SCHEMBL2847980 0.85 DPP4 (0.46) MAPTNPC1RAB9ADPP7DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 MAPT 3150/4885TP53 3969/4885LMNA 4632/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 MAPT 3522/4885TP53 4239/4885LMNA 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.